Topical rapamycin for facial angiofibromas in tuberous sclerosis complex

Area of Science:

• Dermatology
• Genetics
• Pharmacology

Background:

• Facial angiofibromas are a frequent dermatological sign of tuberous sclerosis complex (TSC).
• These benign tumors, while often asymptomatic, can cause significant disfigurement and negatively impact patients' quality of life.
• Current treatment options for facial angiofibromas are limited and often challenging.

Observation:

• A case report details the treatment of a 27-year-old woman with facial angiofibromas associated with TSC.
• The patient presented with significant cosmetic concerns due to the angiofibromas.
• The focus was on evaluating the efficacy and safety of a novel topical treatment.

Findings:

• Topical rapamycin was administered to treat the patient's facial angiofibromas.
• The treatment resulted in successful reduction of the angiofibromas.
• No significant adverse side effects were reported during the treatment period.

Implications:

• Topical rapamycin presents a potentially effective and safe therapeutic option for managing facial angiofibromas in tuberous sclerosis complex patients.
• This approach may offer an improved quality of life for individuals affected by TSC-related facial disfigurement.
• Further clinical studies are warranted to confirm these findings in a larger patient cohort.